AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Q2 2023 Earnings Call Transcript

Laura Suriel: Got it. And then also, I know focus right now is on Niyad, but for your other for LTX-608 candidate, do you have any prospective time lines on when Phase 2 trials might begin on its designated indications of DIC or COVID or ARDS?

Vince Angotti: No. Right now, we’re going to continue to remain focused on getting this first indication across the finish line with anticoagulation of the dialysis circuit as well as our prefilled syringe candidates. I think those on the table for us are enough for our resources to do as efficiently as possible right now. So our focus will remain there.

Laura Suriel: Understood. Thank you taking questions.

Vince Angotti: Thank you, Laura.

Operator: This concludes our question-and-answer session. I would like to turn the conference back over…

Vince Angotti: To Vince.

Operator: …to Vince, I’m sorry, and for closing remarks.

Vince Angotti: Thank you, operator. And again, thank you for joining us today and for your continued support of AcelRx. We remain absolutely focused on driving long-term shareholder value as a newly focused company with late-stage development, high-value assets going forward. We’re very pleased that our plan has attracted new investors, and we look very much forward to the key milestones outlined for not only the balance of 2023 but throughout 2024 as well. So please feel free to contact us after the call if you have any additional questions, and we look forward to sharing our future developments. We believe it’s very exciting moving forward. Thank you.

Operator: The conference has now concluded. Thank you for attending today’s presentation. You may now disconnect.